We excluded cases that did not have a complete set of recordings during the three phases, and also those whose amplitudes were too small to be analyzed by the RETeval system. In the end, 79 cases were analyzed and 9 cases were excluded.
Demographics of all cases (Figures 2 and 3, Table 2)
The mean age of the patients was 68.9 ± 12.6 years, and they were made up of 44 men and 35 women. The mean ± standard deviation of the implicit time in the injected eye was 31.2 ± 3.18 at phase 1, 31.7 ± 3.06 at phase 2, and 32.2 ± 3.31 msec at phase 3, and that in the non-injected fellow eye was 30.5 ± 3.30 at phase 1, 31.1±3.18 at phase 2, and 31.3 ± 3.39 msec at phase 3. The differences in the implicit times between phase 1 and phase 2, and between phase 1 and phase 3 were significant in both the injected and non-injected fellow eyes.
The amplitudes in the injected eyes were 8.66 ± 5.72 µV at phase 1, 7.88 ± 6.07 µV at phase 2, and 9.46 ± 8.93 µV at phase 3, and that in the non-injected fellow eye was 9.41 ± 6.48 µV at phase 1, 9.15 ± 6.66 µV at phase 2, and 9.51 ± 6.19 µV at phase 3. The differences in the amplitudes between the two eyes were not significant at any phase.
Subgroup analysis by disease (Figure 2; Table 3)
Thirty-seven eyes of 37 patients had AMD (mean age 74.1 ± 8.58 years, 24 men and 13 women), 24 eyes of 24 patients had DME (mean age 59.9 ± 11.3 years, 14 men and 10 women), and 18 eyes of 18 patients had RVO with ME (mean age 70.1 ± 14.9 years, 6 men and 12 women).
In the AMD group,18 eyes were injected with ranibizumab and 19 eyes injected with aflibercept. The mean implicit time in the injected eye was 29.9 ± 1.75 msec at phase 1, 30.4 ± 1.64 msec at phase 2, and 30.8 ± 2.14 msec at phase 3, and that in the non-injected fellow eye was 29.5 ± 2.46 msec at phase 1, 30.4 ± 2.11 msec at phase 2, and 30.6 ± 2.35 msec at phase 3. Significant differences in the implicit times between phase 1 and phase 2, and between phase 1 and phase 3 were found in both the injected and non-injected eyes.
The mean amplitude in the injected eye was 8.99 ± 5.74 µV at phase 1, 8.12 ± 6.43 µV at phase 2, and 9.04 ± 6.34 µV at phase 3, and that in the non-injected fellow eye was 10.1 ± 7.16 µV at phase 1, 9.63 ± 7.27 µV at phase 2, and 9.81 ± 6.18 µV at phase 3. No significant difference was observed in the amplitudes for both eyes.
The DME group included 18 eyes injected with ranibizumab and 6 eyes injected with aflibercept. The mean implicit time in the injected eye was 33.6 ± 3.22 msec at phase 1, 34.2 ± 3.15 msec at phase 2, and 34.7 ± 3.09 msec at phase 3, and that in the non-injected fellow eye was 33.6 ± 3.10 msec at phase 1, 34.1 ± 3.10 msec at phase 2, and 34.3 ± 3.40 msec at phase 3. The difference in the implicit times between phase 1 and 3 was significant in the injected and non-injected fellow eyes. No significant difference was observed between phase 1 and 2 in the injected and non-injected fellow eyes.
The mean amplitudes in the injected eye was 7.95 ± 5.88 µV at phase 1, 7.05 ± 5.83 µV at phase 2, and 7.56 ± 5.88 uV at phase 3, and that in the non-injected fellow eye was 7.53 ± 5.13 µV at phase 1, 7.15 ± 5.47 µV at phase 2, and 7.81 ± 5.59 µV at phase 3. No significant difference was observed in the amplitudes for any of the comparisons for both eyes.
The RVO with ME group included 14 eyes injected with ranibizumab, 3 eyes injected with aflibercept, and 1 eye injected with bevacizumab. The mean implicit times of the injected eye was 30.7 ± 3.68 msec at phase 1, 31.3 ± 3.37 msec at phase 2, and 31.6 ± 3.79 msec at phase 3, and that of the non-injected fellow eyes was 28.4 ± 1.93 msec at phase 1, 28.6 ± 2.00 msec at phase 2, and 28.9 ± 2.30 msec at phase 3. Significant differences between phase 1 and phase 2, and between phase 1 and phase 3 were observed only in the injected eyes.
The mean amplitude in the injected eye was 8.94 ± 5.72 µV at phase 1, 8.50 ± 5.82 µV at phase 2, and 12.9 ± 14.7 µV at phase 3, and that in the non-injected fellow eye was 10.5 ± 6.43 µV at phase 1, 10.8 ± 6.47 µV at phase 2, and 11.2 ± 6.74 µV at phase 3. No significant differences were observed for any comparisons in both eyes.
Subgroup analysis for different injected agents (Figure 3, Table 4)
Fifty eyes of 50 patients were injected with ranibizumab, 28 eyes of 28 patients were injected with aflibercept, and one eye of one patient was injected with bevacizumab. The eyes injected with ranibizumab were compared to the eyes injected with aflibercept. The mean age of the ranibizumab group (22 men, 28 women) was 68.1 ± 13.5 years, and 18 eyes had AMD, 18 eyes had DME, and 14 eyes had RVO with ME. The mean implicit time in the injected eye was 31.6 ± 3.45 msec at phase 1, 32.0 ± 3.45 msec at phase 2, and 32.5 ± 3.57 msec at phase 3, and that of the non-injected fellow eye was 30.8 ± 3.24 msec at phase 1, 31.3 ± 3.51 msec at phase 2, and 31.5 ± 3.62 msec at phase 3. Significant differences between phase 1 and 2, and between phase1 and 3 were observed in both the injected and non-injected eyes.
The mean amplitude of the injected eye was 7.18 ± 5.34 µV at phase 1, 6.68 ± 5.60 µV at phase 2, and 8.21 ± 9.97 µV at phase 3, and that in the non-injected fellow eye was 8.21 ± 6.00 µV at phase 1, 7.32 ± 4.79 µV at phase 2, and 8.31 ± 5.54 µV at phase 3. No significant differences were found for any comparisons in both eyes.
The mean age of the aflibercept-injected group (21 men, 7 women) was 70.1 ± 11.0 years, and 19 eyes had AMD, 6 eyes had DME, and 3 eyes had RVO with ME. The mean implicit time in the injected eye was 30.9 ± 2.43 msec at phase 1, 31.4 ± 2.09 msec at phase 2, and 31,8 ± 2.55 msec at phase 3, and that of the non-injected fellow eyes was 30.2 ± 3.33 msec at phase 1, 31.0 ± 2.36 msec at phase 2, and 31.3 ± 2.85 msec at phase 3. Significant differences between phase 1 and 2 and between phase1 and 3 were observed in the injected eyes, and significant difference was observed only between phase1 and 3 in the non-injected eyes.
The mean amplitude in the injected eye was 11.5 ± 5.41 µV at phase 1, 10.0 ± 6.49 µV at phase 2, and 11.8 ± 6.45 µV at phase 3, and that in the non-injected fellow eyes was 11.7 ± 6.86 µV at phase 1, 12.5 ± 8.23 µV at phase 2, and 11.8 ± 6.80 µV at phase 3. No significant difference was observed in any comparisons in both eye.
None of the eyes had a serious complication during the course of this study.